SCHEMBL17507455

SCHEMBL17507455

N#CCc1ccc(/N=C/c2cc(Cl)ccc2O)cc1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 6/20 0.62
▸ CA12 O43570 3/20 0.56
▸ CA2 P00918 3/20 0.56
▸ CA9 Q16790 3/20 0.56
▸ MAOB P27338 2/20 0.56
▸ SMN1; SMN2 Q16637 2/20 0.55
▸ LMNA P02545 1/20 0.55
▸ MAPT P10636 3/20 0.51
▸ KMT2A Q03164 2/20 0.51
▸ HSD17B10 Q99714 3/20 0.46
▸ HPGD P15428 2/20 0.46
▸ CYP2D6 P10635 1/20 0.46
▸ GAA P10253 1/20 0.45
▸ TAAR1 Q96RJ0 1/20 0.45
▸ NPSR1 Q6W5P4 2/20 0.45
▸ KDM4E B2RXH2 2/20 0.45
▸ MEN1 O00255 1/20 0.45
▸ CASP1 P29466 3/20 0.44
▸ GUSB P08236 1/20 0.44
▸ CA1 P00915 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13982232 0.85 MEN1 (0.63) ALDH1A1CA12CA2CA9MAPT
SCHEMBL12767321 0.84 MAOB (0.56) ALDH1A1CA2MAOBSMN1; SMN2LMNA
SCHEMBL15600616 0.84 SMN1; SMN2 (0.62) ALDH1A1CA12CA2CA9MAOB
SCHEMBL13639898 0.84 ALDH1A1 (0.42) ALDH1A1CA12CA2CA9MAOB
SCHEMBL11407794 0.82 ALDH1A1 (0.81) ALDH1A1CA12CA2CA9MAOB
SCHEMBL11407791 0.82 ALDH1A1 (0.81) ALDH1A1CA12CA2CA9MAOB
SCHEMBL30342590 0.82 ALDH1A1 (0.81) ALDH1A1CA12CA2CA9MAOB
SCHEMBL13639899 0.82 ALDH1A1 (0.67) ALDH1A1CA12CA2CA9MAOB
SCHEMBL12858528 0.79 LMNA (0.66) ALDH1A1CA12CA2CA9MAOB
SCHEMBL12767271 0.77 MEN1 (0.58) ALDH1A1CA12CA2CA9MAOB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9981901-B2 IRE-1α inhibitors FOSUN ORINOVE PHARMATECH, INC. (CN) 2018-05-29 — — US disclosed
US-20170152206-A1 IRE-1alpha INHIBITORS FOSUN ORINOVE PHARMATECH, INC. (CN) 2017-06-01 — — US disclosed
EP-3150589-A1 IRE-1A INHIBITORS MannKind Corporation (US) 2017-04-05 — — EP disclosed
EP-2155643-B1 IRE-1A INHIBITORS MANNKIND CORP (US) 2016-08-10 — — EP disclosed
EP-2520561-B1 IRE-1A Inhibitors MANNKIND CORP (US) 2016-02-10 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170152206-A1 IRE-1alpha INHIBITORS XBP1, DDIT3, ERN1 ALDH1A1 2586/4885CA12 4808/4885CA2 3345/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback